{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T19:23:52Z","timestamp":1758050632464,"version":"3.44.0"},"reference-count":7,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.bulcan.2021.04.005","type":"journal-article","created":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T00:39:34Z","timestamp":1621384774000},"page":"563-565","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Nouvelles AMMS\u00a0: carfilzomib associ\u00e9 au daratumumab et \u00e0 la dexamethasone dans le my\u00e9lome multiple r\u00e9fractaire ou en rechute ayant re\u00e7u au moins une ligne th\u00e9rapeutique"],"prefix":"10.1016","volume":"108","author":[{"given":"M\u00e9lanie","family":"Try","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lionel","family":"Karlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2021.04.005_bib0040","unstructured":"GLOBOCAN 2020. Global Prevalence and Incidence. Disponible sur le site: https:\/\/gco.iarc.fr\/today\/data\/factsheets\/cancers\/35-Multiple-myeloma-fact-sheet.pdf. Visualis\u00e9 le 26\/12\/2020."},{"issue":"1","key":"10.1016\/j.bulcan.2021.04.005_bib0045","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","article-title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study","volume":"17","author":"Dimopoulos","year":"2016","journal-title":"The Lancet Oncology"},{"issue":"2","key":"10.1016\/j.bulcan.2021.04.005_bib0050","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.bulcan.2021.04.005_bib0055","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1038\/s41375-020-0711-6","article-title":"Daratumumab plus lenalidomide and dexamethasone in relapsed\/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3\u00a0study","volume":"34","author":"Bahlis","year":"2020","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.bulcan.2021.04.005_bib0060","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1182\/blood.2019000722","article-title":"Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"134","author":"Chari","year":"2019","journal-title":"Blood"},{"issue":"10245","key":"10.1016\/j.bulcan.2021.04.005_bib0065","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0140-6736(20)30734-0","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3\u00a0study","volume":"396","author":"Dimopoulos","year":"2020","journal-title":"The Lancet"},{"issue":"7","key":"10.1016\/j.bulcan.2021.04.005_bib0035","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S1470-2045(18)30354-1","article-title":"Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3\u00a0study","volume":"19","author":"Moreau","year":"2018","journal-title":"The Lancet Oncology"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455121001764?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455121001764?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T19:33:55Z","timestamp":1757792035000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455121001764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":7,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S0007455121001764"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2021.04.005","relation":{},"ISSN":["0007-4551"],"issn-type":[{"type":"print","value":"0007-4551"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nouvelles AMMS\u00a0: carfilzomib associ\u00e9 au daratumumab et \u00e0 la dexamethasone dans le my\u00e9lome multiple r\u00e9fractaire ou en rechute ayant re\u00e7u au moins une ligne th\u00e9rapeutique","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2021.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}